BfR Germany Assesses Oral Hexahydrocannabinol (HHC) Risks in Food-Like Products

The landscape of cannabinoid derivatives continues to evolve rapidly, presenting both opportunities and regulatory challenges for the supplement and nutraceutical industry. Recently, Germany's Federal Institute for Risk Assessment (BfR) highlighted a significant concern regarding Hexahydrocannabinol (HHC), issuing a toxicological evaluation for its oral consumption.

This assessment by the BfR stems from reports of HHC-containing products being illicitly available on the German market, often masquerading as conventional foodstuffs, such as gummy candies. For manufacturers like us, this scenario underscores the critical importance of robust supply chain diligence and adherence to national legislation across all target markets, particularly within the diverse regulatory environment of the European Union.

“The BfR's findings serve as a crucial reminder for all stakeholders in the supplement industry to exercise extreme caution with novel cannabinoids, especially when they blur the lines between recreational substances and dietary supplements.”

Implications for Product Development and Compliance

From a formulation standpoint, the alarm raised by the BfR on HHC necessitates a clear strategy: if an ingredient lacks comprehensive safety data and clear regulatory approval for food or supplement use, it should be approached with considerable caution. This is particularly true for novel compounds whose 'food-like' presentation could mislead consumers and attract greater scrutiny from authorities like the BfR or the Food Standards Agency (FSA) in the UK.

Brand owners should immediately review their product portfolios and supply chains to ensure no HHC-containing substances are inadvertently present, especially if operating in or considering entry into the German market. The presence of such substances, particularly those deemed 'illicit' and presented in forms easily mistaken for food, poses not only regulatory risks but also significant reputational damage.

The Broader Industry Context

This situation also highlights a broader trend: as consumer interest in cannabinoids grows, so does the proliferation of novel derivatives. While some, like CBD, have established (though still evolving) regulatory frameworks, others like HHC emerge into a grey area, prompting rapid toxicological assessments from national bodies. For contract manufacturers, staying ahead of these developments means meticulous vigilance over raw material sourcing and proactive advice to clients on compliance. It’s about ensuring that the innovative products brought to market are not only effective but, crucially, unequivocally safe and legally compliant.

The BfR's intervention serves as a clear signal that regulatory bodies are closely monitoring new cannabinoid entries into the market, especially those with intoxicating effects or presented deceptively. This reinforces the need for our industry to prioritise consumer safety and transparent product development above all else.

Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.